Zhitong Finance App News, Shiyao Group (01093.HK) announced that CRB-701 (SYS6002), which the group authorized CorbusPharmaceuticals, Inc. (Corbus) to develop, has been approved by the US Food and Drug Administration (FDA) to launch a registered clinical trial (trial code: TEMPO-1) for second-line (2L) treatment of oropharyngeal squamous cell carcinoma (OPSCC).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.